Japanese Government Procurement

National University Corporation - Notice of Procurement (Goods & Services)Pembrolizumab (Genetical Recombination) 100mg/4mL 1vial/case about 3560cases,and 93 other contracts

This procurement is covered by the WTO Agreement on Government Procurement, Japan-EU Economic Partnership Agreement or Japan-UK Comprehensive Economic Partnership Agreement.

Japanese

Publishing date Apr 16, 2026
Type of notice Notice of Procurement (Goods & Services)
Procurement entity National University Corporation - Ibaraki
Classification
0004 Medical & Pharmaceutical Products
Summay of notice ⑴ Official in charge of disbursement of the procuring entity : HIRAMASTU Yuji, The Obligating Officer Director, University of Tsukuba Hospital
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Pembrolizumab (Genetical Recombination) 100mg/4mL 1vial/case about 3560cases
B Nivolumab (Genetical Recombination) 240mg/24mL 1vial/case about 1620cases
C Vutrisiran Sodium 25mg/0.5mL 1syringe/case about 20cases
D Daratumumab (Genetical Recombination)・Vorhyaluronidase Alfa (Genetical Recombination) 15mL 1vial/case about 580cases
E Efgartigimod Alfa (Genetical Recombination) 400mg/20mL 1vial/case about 650cases
F Durvalumab (Genetical Recombination) 500mg/10mL 1vial/case about 720cases
G Elranatamab (Genetical Recombination) 76mg/1.9mL 1vial/case about 190cases
H Teprotumumab (Genetical Recombination) 500mg 1vial/case about 190cases
I Epcoritamab (Genetical Recombination) 48mg/0.8mL 1vial/case about 60cases
J Ipilimumab (Genetical Recombination) 50mg/10mL 1vial/case about 250cases
K Amivantamab (Genetical Recombination) 350mg/7mL 1vial/case about 390cases
L Risankizumab (Genetical Recombination) 150mg/1mL 1syringe/case about 330cases
M Paclitaxel 100mg 1vial/case about 3230cases
N Canakinumab (Genetical Recombination) 150mg/1mL 1vial/case about 70cases
O Risankizumab (Genetical Recombination) 360mg/2.4mL 1kit/case about 200cases
P Trastuzumab Deruxtecan (Genetical Recombination) 100mg 1vial/case about 540cases
Q Lenalidomide Hydrate 5mg 40capsules/case about 320cases
R Atezolizumab (Genetical Recombination) 1200mg/20mL 1vial/case about 190cases
S Blinatumomab (Genetical Recombination) 35㎍ 1vial/case about 270cases
T Aflibercept (Genetical Recombination) 40mg 1syringe/case about 1040cases
U Efgartigimod Alfa (Genetical Recombination) ・Vorhyaluronidase Alfa (Genetical Recombination) 5mg 1syringe/case about 150cases
V Avelumab (Genetical Recombination) 200mg 1vial/case about 730cases
W Avalglucosidase Alfa (Genetical Recombination) 100mg 1vial/case about 520cases
X Sotatercept (Genetical Recombination) 45mg 1vial/case about 80cases
Y Aflibercept (Genetical Recombination) 8mg 1syringe/case about 510cases
Z Datopotamab Deruxtecan (Genetical Recombination) 100mg 1vial/case about 170cases
AA Sacituzumab Govitecan (Genetical Recombination) 200mg 1vial/case about 330cases
AB Nirsevimab (Genetical Recombination) 50mg/0.5mL 1syringe/case about 160cases
AC Polyethylene Glycol Treated Human Normal Immunoglobulin 10g/100mL 1vial/case about 790cases
AD Faricimab (Genetical Recombination) 6mg/0.05mL 1syringe/case about 530cases
AE Letermovir 240mg 14tablets/case about 350cases
AF Romiplostim (Genetical Recombination) 250㎍ 1vial/case about 1440cases
AG Irinotecan Hydrochloride Hydrate 43mg/10mL 1vial/case about 530cases
AH pH4-Treated Normal Human Immunoglobulin 10g/100mL 1vial/case about 520cases
AI Enfortumab Vedotin (Genetical Recombination) 30mg 1vial/case about 850cases
AJ Brentuximab Vedotin (Genetical Recombination) 50mg 1vial/case about 180cases
AK Infliximab (Genetical Recombination) 100mg 1vial/case about 1270cases
AL Denosumab (Genetical Recombination) 120mg/1mL 1syringe/case about 1210cases
AM Evinacumab (Genetical Recombination) 345mg/2.3mL 1vial/case about 40cases
AN Ramucirumab (Genetical Recombination) 500mg/50mL 1vial/case about 160cases
AO Tarlatamab (Genetical Recombination) 10mg 1vial/case about 40cases
AP Trastuzumab Emtansine (Genetical Recombination) 100mg 1vial/case about 170cases
AQ Pegfilgrastim (Genetical Recombination) 3.6mg/0.36mL 1kit/case about 600cases
AR pH4-Treated Normal Human Immunoglobulin 20g/200mL 1vial/case about 270cases
AS Tremelimumab (Genetical Recombination) 300mg/15mL 1vial/case about 10cases
AT Ustekinumab (Genetical Recombination) 45mg/0.5mL 1syringe/case about 280cases
AU Abatacept (Genetical Recombination) 250mg 1vial/case about 860cases
AV Maribavir 200mg 28tablets/case about 30cases
AW Inebilizumab (Genetical Recombination) 100mg/10mL 3vials/case about 5cases
AX Cetuximab (Genetical Recombination) 100mg/20mL 1vial/case about 1750cases
AY Guselkumab (Genetical Recombination) 100mg/1mL 1syringe/case about 130cases
AZ Fosnetupitant Chloride Hydrochloride 235mg 5vials/case about 690cases
BA Zolbetuximab (Genetical Recombination) 100mg 1vial/case about 760cases
BB Obinutuzumab (Genetical Recombination) 1000mg/40mL 1vial/case about 120cases
BC Leuprorelin Acetate 11.25mg 1syringe/case about 900cases
BD Nirsevimab (Genetical Recombination) 100mg/1mL 1syringe/case about 50cases
BE Azacitidine 100mg 1vial/case about 1530cases
BF Bevacizumab (Genetical Recombination) 400mg/16mL 1vial/case about 460cases
BG Vedolizumab (Genetical Recombination) 300mg 1vial/case about 130cases
BH Lyophilized Human C1-inactivator Concentrate 500 1vial/case about 380cases
BI Lanreotide Acetate 120mg 1syringe/case about 80cases
BJ Mepolizumab (Genetical Recombination) 100mg/1mL 1kit/case about 210cases
BK Pomalidomide 4mg 7capsules/case about 70cases
BL Sotatercept (Genetical Recombination) 60mg 1vial/case about 20cases
BM Leuprorelin Acetate 22.5mg 1syringe/case about 420cases
BN Palonosetron Hydrochloride 0.75mL/50mL 1pack/case about 1320cases
BO Trastuzumab Emtansine (Genetical Recombination) 160mg 1vial/case about 60cases
BP Nivolumab (Genetical Recombination) 20mg/2mL 1vial/case about 870cases
BQ Golimumab (Genetical Recombination) 50mg/0.5mL 1kit/case about 380cases
BR Pomalidomide 3mg 7capsules/case about 110cases
BS Guselkumab (Genetical Recombination) 200mg/2mL 1kit/case about 60cases
BT Selexipag 0.4mg 30tablets/case about 230cases
BU Ofatumumab (Genetical Recombination) 20mg/0.4mL 1kit/case about 170cases
BV Fulvestrant 250mg/5mL 2syringes/case about 380cases
BW Bevacizumab (Genetical Recombination) 400mg/16mL 1vial/case about 1310cases
BX Pegfilgrastim (Genetical Recombination) [Pegfilgrastim Biosimilar 1] 3.6mg/0.36mL 1syringe/case about 650cases
BY Rituximab (Genetical Recombination) [Rituximab Biosimilar1] 500mg/50mL 1vial/case about 660cases
BZ Elotuzumab (Genetical Recombination) 300mg 1vial/case about 240cases
CA Panitumumab (Genetical Recombination) 400mg 1vial/case about 100cases
CB Atovaquone 750mg/5mL 14packs/case about 670cases
CC Anifrolumab (Genetical Recombination) 300mg/2mL 1vial/case about 230cases
CD Enfortumab Vedotin (Genetical Recombination) 20mg 1vial/case about 390cases
CE Tazobactam Sodium-Piperacillin Sodium for Injection 4.5g 10vials/case about 2290cases
CF Tildrakizumab (Genetical Recombination) 100mg 1syringe/case about 40cases
CG Panitumumab (Genetical Recombination) 100mg 1vial/case about 370cases
CH Clazosentan Sodium 150mg 10vials/case about 40cases
CI Macitentan 10mg 30tablets/case about 50cases
CJ Doxorubicin Hydrochloride 20mg/10mL 1vial/case about 440cases
CK Pomalidomide 2mg 7capsules/case about 120cases
CL Bimekizumab (Genetical Recombination) 320mg/2mL 1kit/case about 60cases
CM Ramucirumab (Genetical Recombination) 100mg/10mL 1vial/case about 450cases
CN Freeze-dried Polyethylene Glycol Treated Human Normal Immunoglobulin 5000mg 1vial/case about 510cases
CO Tisotumab Vedotin (Genetical Recombination) 40mg 1vial/case about 80cases
CP Eptacog Alfa (Activated) (Genetical Recombination) 5mg 1kit/case about 50cases
⑷ Delivery period : From 1 July, 2026 through 31 March, 2027
⑸ Delivery place : The University of Tsukuba Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A not come under Article 46 and 47 of the Regulation concerning the Contract for University of Tsukuba Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B have the Grade A,Grade B or Grade C qualification during fiscal 2026 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by The Obligating Officer,
E meet the qualification requirements which The Obligating Officer Director may specify in accordance with Article 49 of the Regulation,
F not be currently under a suspension of business order as instructed by The Obligating Officer.
⑺ Time limit of tender : 10 : 00 8 June, 2026
⑻ Contact point for the notice : MURASAWA Yuki, Division of Accounting, Department of University Hospital Management, University of Tsukuba, 2-1-1 Amakubo Tsukuba-shi 305-8576 Japan, TEL 029-853-3543
⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.